ESSA Pharma Future Growth

Future criteria checks 3/6

ESSA Pharma is forecast to grow earnings and revenue by 43.8% and 45.3% per annum respectively while EPS is expected to grow by 44.2% per annum.

Key information

43.8%

Earnings growth rate

44.2%

EPS growth rate

Biotechs earnings growth	27.3%
Revenue growth rate	45.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	04 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:EPIX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2027	58	26	-132	N/A	3
9/30/2026	6	-18	-94	N/A	4
9/30/2025	N/A	-24	-63	N/A	4
9/30/2024	N/A	-31	-32	N/A	5
6/30/2024	N/A	-28	-24	-24	N/A
3/31/2024	N/A	-28	-23	-23	N/A
12/31/2023	N/A	-26	-22	-22	N/A
9/30/2023	N/A	-27	-20	-20	N/A
6/30/2023	N/A	-27	-23	-23	N/A
3/31/2023	N/A	-29	-24	-24	N/A
12/31/2022	N/A	-33	-27	-27	N/A
9/30/2022	N/A	-35	-28	-28	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-37	-28	-28	N/A
12/31/2021	N/A	-39	-27	-27	N/A
9/30/2021	N/A	-37	-25	-25	N/A
6/30/2021	N/A	-33	-22	-22	N/A
3/31/2021	N/A	-29	-19	-19	N/A
12/31/2020	N/A	-25	-18	-18	N/A
9/30/2020	N/A	-23	-17	-17	N/A
6/30/2020	N/A	-22	-18	-18	N/A
3/31/2020	N/A	-21	-17	-17	N/A
12/31/2019	N/A	-15	-14	-14	N/A
9/30/2019	N/A	-13	-12	-12	N/A
6/30/2019	N/A	-12	-9	-9	N/A
3/31/2019	N/A	-11	-10	-10	N/A
12/31/2018	N/A	-12	-10	-10	N/A
9/30/2018	N/A	-12	-10	-10	N/A
6/30/2018	N/A	-11	-11	-11	N/A
3/31/2018	N/A	-5	N/A	-13	N/A
12/31/2017	N/A	-8	N/A	-13	N/A
9/30/2017	N/A	-4	N/A	-17	N/A
6/30/2017	N/A	-7	N/A	-18	N/A
3/31/2017	N/A	-14	N/A	-16	N/A
12/31/2016	N/A	-8	N/A	-19	N/A
9/30/2016	N/A	-13	N/A	-15	N/A
6/30/2016	N/A	-8	N/A	-17	N/A
3/31/2016	N/A	-10	N/A	-18	N/A
12/31/2015	N/A	-12	N/A	-14	N/A
9/30/2015	N/A	-10	N/A	-13	N/A
6/30/2015	N/A	-11	N/A	-10	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-3	N/A	-4	N/A
9/30/2014	N/A	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPIX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: EPIX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EPIX is expected to become profitable in the next 3 years.

Revenue vs Market: EPIX is forecast to have no revenue next year.

High Growth Revenue: EPIX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EPIX's Return on Equity is forecast to be high in 3 years time

ESSA Pharma Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Forecast to breakeven in 2027

Recent updates

Forecast to breakeven in 2027

New minor risk - Market cap size

ESSA Pharma Inc. Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies